Prevalence of depression and anxiety in patients with cystic fibrosis and parent caregivers: results of The International Depression Epidemiological Study across nine countries
Autores de IIS La Fe
Participantes ajenos a IIS La Fe
- Quittner AL
- Goldbeck L
- Abbott J
- Duff A
- Lambrecht P
- Tibosch MM
- Bergsten Brucefors A
- Yüksel H
- Catastini P
- Blackwell L
- Barker D
Grupos
Abstract
Background Individuals with chronic diseases and parent caregivers are at increased risk for symptoms of depression and anxiety. Prevalence of psychological symptoms was evaluated in adolescents and adults with cystic fibrosis (CF) and parent caregivers across nine countries. Methods Patients with CF, ages 12 years and older, and caregivers of children with CF, birth to 18 years of age, completed measures of depression and anxiety across 154 CF centres in Europe and the USA. Psychological symptoms were compared across countries using chi(2). Logistic regression examined extent of comorbid symptoms, predictors of depression and anxiety, and concordance between parent and adolescent symptomatology. Results Psychological symptoms were reported by 6088 patients with CF and 4102 parents. Elevated symptoms of depression were found in 10% of adolescents, 19% of adults, 37% of mothers and 31% of fathers. Elevations in anxiety were found in 22% of adolescents, 32% of adults, 48% of mothers and 36% of fathers. Overall, elevations were 2-3 times those of community samples. Participants reporting elevated anxiety were more likely to report depression (ORs: adolescents=14.97, adults=13.64, mothers=15.52, fathers=9.20). Significant differences in reports of depression and anxiety were found by patient age and parent respondent. Concordance between 1122 parent-teen dyads indicated that adolescents whose parents reported depression were more likely to be elevated on depression (OR=2.32). Similarly, adolescents whose parents reported anxiety were more likely to score in the elevated range on the anxiety measure (OR=2.22). Conclusions Symptoms of depression and anxiety were elevated in both patients with CF and parents across several European countries and the USA. Annual screening of psychological symptoms is recommended for both patients and parents.
Datos de la publicación
- ISSN/ISSNe:
- 0040-6376, 1468-3296
- Tipo:
- Article
- Páginas:
- 1090-1097
- PubMed:
- 25246663
- Factor de Impacto:
- 3,776 SCImago ℠
- Cuartil:
- Q1 SCImago ℠
Thorax BMJ PUBLISHING GROUP
Citas Recibidas en Web of Science: 307
Documentos
- No hay documentos
Filiaciones
Keywords
- Cystic Fibrosis; Paediatric Lung Disaese; Psychology
Proyectos y Estudios Clínicos
ADMINISTRACIÓN A LARGO PLAZO DE MANITOL INHALADO EN FIBROSIS QUÍSTICA: ESTUDIO DE SEGURIDAD Y EFICACIA EN PACIENTES ADULTOS CON FIBROSIS QUÍSTICA.
Investigador Principal: AMPARO SOLÉ JOVER
DPM-CF-303 . 2014
ESTUDIO DE EXTENSIÓN DE FASE 3 PARA EVALUAR LA SEGURIDAD Y LA EFICACIA DEL TRATAMIENTO A LARGO PLAZO CON LUMACAFTOR EN COMBINACIÓN CON IVACAFTOR EN SUJETOS DE 12 AÑOS O MÁS CON FIBROSIS QUÍSTICA, HOMOCIGÓTICOS O HETEROCIGÓTICOS PARA LA MUTACIÓN F508DEL-CF TR.
Investigador Principal: AMPARO SOLÉ JOVER
VX12-809-105 . 2014
ESTUDIO DE FASE IV, ABIERTO, CRUZADO, DE INTERVENCIÓN PARA COMPARAR LA FACILIDAD DE USO DE TOBRAMICINA POLVO PARA INHALACIÓN FRENTE A TOBRAMICINA SOLUCIÓN PARA INHALACIÓN Y COLISTIMETATO NEBULIZADO PARA EL TRATAMIENTO DE LA INFECCIÓN PULMONAR POR PSEUDOM ONAS AERUGINOSA PULMONAR EN PACIENTES CON FIBROSIS QUÍSTICA.
Investigador Principal: AMPARO SOLÉ JOVER
CTBM100C2403 . 2013
ESTUDIO DE BÚSQUEDA DE DOSIS EN FASE II, MULTICÉNTRICO, CON GRUPO PARALELO, CON COMPARADOR ACTIVO, ALEATORIZADO Y DOBLE CIEGO PARA EVALUAR LA EFICACIA Y LA SEGURIDAD DE DOSIS DIFERENTES DE KREON DE LIBERACIÓN INMEDIATA EN SUJETOS CON INSUFICIENCIA PANCREÁ TICA EXOCRINA DEBIDA A FIBROSIS QUÍSTICA.
Investigador Principal: AMPARO SOLÉ JOVER
PANC2002 . 2015
ESTUDIO OBSERVACIONAL PROSPECTIVO MULTICÉNTRICO PARA EVALUAR LA RESPUESTA INMUNÓLOGICA ESPECIFICA FRENTE A CITOMEGALOVIRUS (CMV) MEDIDA POR QUANTIFERON® Y LA RESPUESTA INMUNOLÓGICA GLOBAL MEDIDA POR IMMUKNOW® EN PACIENTES TRASPLANTADOS DE PULMÓN CON SEROL OGÍA CMV PREVIA AL TRASPLANTE POSITIVA (R+) Y SU IMPLICACIÓN EN EL DESARROLLO DE INFECCIÓN POR CMV.
Investigador Principal: AMPARO SOLÉ JOVER
FUN-CMV-2013-01 . 2013
ESTUDIO DE SEGURIDAD Y TOLERABILIDAD A LARGO PLAZO DE LA ADMINISTRACIÓN ABIERTA DE AMIKACINA LIPOSOMAL PARA INHALACIÓN (ARIKACE) EN PACIENTES CON FIBROSIS QUÍSTICA CON INFECCIÓN CRÓNICA POR PSEUDOMONAS AERUGINOSA.
Investigador Principal: AMPARO SOLÉ JOVER
TR02-110 . 2012
UTILIDADES EN SALUD Y CALIDAD DE VIDA, EN PACIENTES ESPAÑOLES CON FIBROSIS QUÍSTICA.
Investigador Principal: AMPARO SOLÉ JOVER
MAI-FQ-2014-01
Cita
Quittner AL,Goldbeck L,Abbott J,Duff A,Lambrecht P,SOLÉ A,Tibosch MM,Bergsten A,Yüksel H,Catastini P,Blackwell L,Barker D. Prevalence of depression and anxiety in patients with cystic fibrosis and parent caregivers: results of The International Depression Epidemiological Study across nine countries. Thorax. 2014. 69. (12):p. 1090-1097. IF:8,290. (1).